Factor VIII prophylaxis effects outweigh other hemostasis contributors in predicting severe haemophilia A joint outcomes.

ABSTRACT:

Introduction

The Joint Outcome Study (JOS) demonstrated that previously untreated children with severe haemophilia A treated with prophylactic factor VIII (FVIII) concentrate had superior joint outcomes at age 6 years compared to those children treated episodically for bleeding. However, variation in joint outcome within each treatment arm was not well explained.

Aim

In this study, we sought to better understand variation in joint outcomes at age 6 years in participants of the JOS.

Methods

We evaluated the influence of FVIII half-life, treatment adherence, constitutional coagulant and anticoagulant proteins, and global assays on joint outcomes (number of joint bleeds, total number of bleeds, total MRI score and joint physical exam score). Logistic regression was used

SUBMITTER: Warren BB 

PROVIDER: S-EPMC7273872 | biostudies-literature | 2019 Sep

REPOSITORIES: biostudies-literature